Compare SOPH & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | PROF |
|---|---|---|
| Founded | 2011 | N/A |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 270.7M |
| IPO Year | 2021 | 2017 |
| Metric | SOPH | PROF |
|---|---|---|
| Price | $4.70 | $6.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.00 | ★ $12.00 |
| AVG Volume (30 Days) | 100.3K | ★ 352.4K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $23.09 | $115.41 |
| Revenue Next Year | $19.57 | $60.63 |
| P/E Ratio | ★ N/A | $4.47 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $2.58 | $3.90 |
| 52 Week High | $5.70 | $8.95 |
| Indicator | SOPH | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 44.60 | 52.14 |
| Support Level | $4.54 | $5.81 |
| Resistance Level | $4.86 | $7.18 |
| Average True Range (ATR) | 0.27 | 0.47 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 24.26 | 74.11 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.